Developer docs
API playgroundTry for free, no card

Search company profiles

Barrett Hodgson

Full company profile

uuid002bd3e

Namestring
Barrett Hodgson
Legal namestring
Barrett Hodgson Pakistan (Pvt.) Ltd.
Company typeenum
Private
Founded yearint
1996
Descriptiontext

Barrett Hodgson Pakistan (Pvt.) Ltd. is a Karachi-headquartered, private pharmaceutical company founded in 1992 and formally inaugurated in 1996. It operates as part of the Habib family enterprise and is owned by The Salim Habib Education Foundation (TSHEF), a non-profit established in 2007 that channels profits into educational initiatives including Barrett Hodgson University in Karachi and Barrett Hodgson College in Toba Tek Singh. The company ranks among the top 15 of approximately 700 pharmaceutical companies in Pakistan by turnover, with disclosed revenue of Rs. 11.28 Billion and a stated target of Rs. 20 Billion.

The company manufactures and distributes a portfolio of more than 100 brands and 240 formulations across cardiovascular, respiratory, anti-infective, ophthalmology, pain management, gastroenterology, diabetes, neurology, and other therapeutic areas; 24 brands lead their respective molecules. Approximately 5 of every 6 product representations originate from co-development partnerships with global MNCs, namely AstraZeneca (Losec, Plendil, Betaloc-ZOK), Astellas (Cefspan, Cefizox), Allergan (Lumigan, Alphagan, Combigan, Botox), LTL Pharma (cephalosporin range), and The Aenova Group (pain management). Manufacturing is cGMP-compliant with a Quality Management System based on ICH, WHO, and PIC/s guidelines; SAP S/4 HANA ERP was deployed in 2018 as the first such implementation in a Pakistani pharma company, and a new sterile area was approved by DRAP in 2020.

The business model is a prescription-driven pharma distribution business monetized through one-time product sales across Pakistan via a 1,100+ strong field force and 72 distributors reaching approximately 2,600 towns, 31,000 pharmacies, and 310+ hospital and institutional customers. Commercial operations are organized into therapeutic divisions led by Deputy Commercial Directors under a layered Area Manager / Regional Head structure, with supporting medical detailing, CME programs, patient awareness camps, and social media marketing. The company is currently expanding manufacturing capacity (sterile, tablet, liquid), constructing a Lahore warehouse, and acquiring a 2-acre plot in Karachi for portfolio diversification beyond pharmaceuticals, consistent with its growth trajectory and CSR commitments under TSHEF.

Short descriptiontext

Barrett Hodgson Pakistan is a Karachi-based pharmaceutical company ranking among Pakistan's top 15, manufacturing and distributing over 100 brands and 240 formulations across cardiovascular, respiratory, ophthalmology, and pain management through a 1,100+ member field force.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersKarachi, Pakistan
HQ citystring
Karachi
HQ countrystring
Pakistan
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, generic medicines, therapeutic formulations, cardiovascular drugs, cephalosporin antibiotics
Industry1 code
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue generated from sale of pharmaceutical products across multiple therapeutic categories through direct sales force and distribution network covering 72 distributors, 2,600 towns, 31,000 pharmacies, and 310+ hospital/institution customers

barretthodgson.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Barrett Hodgson Pakistan manufactures and distributes a portfolio of over 100 pharmaceutical brands and 240 formulations across cardiovascular, respiratory, anti-infective, ophthalmology, pain management, gastroenterology, diabetes, and neurology therapeutic areas. The company also represents products from five global partners including AstraZeneca, Astellas, Allergan, LTL Pharma, and Aenova Group across Pakistan through a 72-distributor network covering 2,600 towns, 31,000 pharmacies, and 310+ hospital/institutional customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Ranked among top 15 pharmaceutical companies in Pakistan out of 700 companies
+2 more records
Product overview1 text field

Barrett Hodgson Pakistan (BHP) is a pharmaceutical company ranking among the top 15 in Pakistan with over 100 brands and 240 formulations. The portfolio includes products from five international business partners: AstraZeneca (cardiovascular/respiratory: Losec, Plendil, Betaloc-ZOK), Astellas (cephalosporin antibiotics: Cefspan, Cefizox), Allergan (ophthalmology: Lumigan, Alphagan, Combigan; and therapeutics/cosmetics: Botox), LTL Pharma (cephalosporin range), and The Aenova Group (pain management). Core products span therapeutic areas including cardiovascular, respiratory, anti-infective, ophthalmology, pain management, gastroenterology, diabetes, and neurology. 24 brands are market leaders. The company also operates through The Salim Habib Education Foundation (TSHEF) for CSR and education initiatives, and is diversifying into non-pharmaceutical businesses.

Product and service27 records
1Acicon
2AciReg
CategoryGastroenterology
Description

Esomeprazole 20mg, 40mg Capsule and 40mg IV Infusion for proton pump inhibition; sold through Pakistan pharmacy and hospital distribution.

3Aerokast
CategoryRespiratory
Description

Montelukast sodium 4mg Sachet, 4mg and 5mg Chewable Tabs, 10mg Tabs for respiratory conditions; sold through Pakistan pharmacy and hospital distribution.

4Alphagan Ophthalmic Solution
CategoryOphthalmology
Description

Brimonidine tartrate 0.2% ophthalmic solution for glaucoma; marketed in Pakistan in partnership with Allergan.

5Botox
CategoryAesthetics and Therapeutics
Description

Botulinum Toxin Type A for therapeutic and cosmetic applications, distributed in Pakistan in partnership with Allergan.

6Febrol
CategoryAnalgesics
Description

Paracetamol-based analgesic in Tablet, Suspension and DS Suspension forms for pain and fever management; distributed across Pakistan pharmacies.

7Inocef
CategoryAnti-infectives
Description

Ceftriaxone 250mg and 500mg IM Injection and 250mg, 500mg, 1000mg and 2000mg IV Injection for anti-infective therapy; supplied to Pakistani hospitals and pharmacies.

8Nebicare
CategoryCardiovascular
Description

Nebivolol 2.5mg, 5mg and 10mg Tablet for cardiovascular conditions; launched in 2017 and sold through Pakistani pharmacy and hospital distribution.

9AV-Sartan
CategoryCardiovascular
Description

Amlodipine+Valsartan combination tablet in 5mg+80mg, 5mg+160mg and 10mg+160mg strengths for hypertension; launched in 2017.

10Gutset
CategoryGastroenterology
Description

Itopride Hydrochloride 50mg Tablet for gastrointestinal disorders; launched in 2017.

11Lumigan Ophthalmic Solution
CategoryOphthalmology
Description

Bimatoprost 0.03% ophthalmic solution for glaucoma; marketed in Pakistan in partnership with Allergan.

12Combigan Ophthalmic Solution
CategoryOphthalmology
Description

Brimonidine tartrate/Timolol maleate 0.2%/0.5% ophthalmic solution for glaucoma; marketed in Pakistan in partnership with Allergan.

13Cefspan
CategoryAnti-infectives
Description

Cefixime 100mg/5ml Suspension, 200mg/5ml DS Suspension and 400mg Capsule for anti-infective therapy; marketed in Pakistan in partnership with Astellas.

14Cefizox IV-IM Injection
CategoryAnti-infectives
Description

Ceftizoxime sodium 250mg, 500mg and 1000mg IV/IM Injection for anti-infective therapy; marketed in Pakistan in partnership with Astellas.

15Mobikare
CategoryPain Management
Description

Diclofenac Sodium in Capsule, Injection, Plus Tablet, and Gel formulations for pain management; supported by Aenova Group partnership.

16Diabold
CategoryDiabetes
Description

Glimepiride 1, 2, 3 and 4mg Tablet for diabetes management; distributed through Pakistan pharmacy and hospital network.

17Baristat
CategoryCardiovascular
Description

Febuxostat 40mg and 80mg Tablet for gout management; distributed through Pakistan pharmacy network.

18Rivaclot
CategoryCardiovascular
Description

Rivaroxaban 2.5mg, 10mg, 15mg and 20mg Tablet for anticoagulation therapy; distributed through Pakistan pharmacy network.

19RosuBar
CategoryCardiovascular
Description

Rosuvastatin 5mg, 10mg and 20mg Tablet for lipid management; distributed through Pakistan pharmacy network.

20Neugalin
CategoryNeurology
Description

Pregabalin 25mg, 50mg, 75mg, 100mg and 150mg Capsule for neurological conditions including neuropathic pain.

21S-gliptin
CategoryDiabetes
Description

Sitagliptin and Sitagliptin+Metformin HCI combination tablet for diabetes management.

22Vilcret Plus
CategoryDiabetes
Description

Vildagliptin+Metformin HCI tablet in 50mg+500mg, 50mg+850mg and 50mg+1000mg strengths for diabetes management.

23AstraZeneca Brand Portfolio (Losec, Plendil, Betaloc-ZOK)
CategoryCardiovascular and Respiratory
Description

Cardiovascular and respiratory products from partner AstraZeneca represented in Pakistan including Losec (Omeprazole), Plendil (Felodipine), and Betaloc-ZOK (Metoprolol succinate).

24Astellas Cephalosporin Range (Cefspan, Cefizox)
CategoryAnti-infectives
Description

Cephalosporin antibiotic products from partner Astellas including Cefspan (Cefixime) and Cefizox (Ceftizoxime sodium) in various injectable and oral formulations.

25Allergan Ophthalmology Brand Portfolio (Lumigan, Alphagan, Combigan, Botox)
CategoryOphthalmology
Description

Ophthalmology and therapeutics products from partner Allergan including Lumigan (Bimatoprost), Alphagan (Brimonidine), Combigan (Brimonidine/Timolol), and Botox for therapeutic and cosmetic applications.

26LTL Pharma Cephalosporin Range
CategoryAnti-infectives
Description

Cephalosporin antibiotic range acquired from partner LTL Pharma Co., Ltd. (Japan) ensuring stable supply of original-quality products.

27Aenova Pain Management Portfolio
CategoryPain Management
Description

Pain management products supported by partner The Aenova Group (Germany), a global contract manufacturer with 22 sites across Europe, Asia and USA.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

British-Swedish multinational pharmaceutical company with operations in more than 100 countries. BHP represents AstraZeneca in Pakistan through different therapeutic segments including Cardiovascular and Respiratory. Key brands marketed include Losec, Plendil, and Betaloc-ZOK.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Japanese pharmaceutical company formed in 2005 with merger of Yamanouchi and Fujisawa. BHP represents Astellas in Pakistan through Cephalosporin Antibiotics segment. Markets different formulations of Cefspan and Cefizox.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

US-based global multi-specialty ophthalmic healthcare company established in 1948. BHP markets Allergan's ophthalmology brands including Lumigan, Alphagan, Combigan, and Botox for therapeutics and cosmetics.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Japanese subsidiary of Japan Established Medicine Corporation. Ensures stable supply of products maintaining original product reliability, quality, efficacy and safety. BHP acquires Cephalosporin range from LTL Pharma.

5The Aenova Group
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Global leader in pharmaceutical and healthcare industries with emphasis on innovative technologies and high quality standards. One of the leading contract manufacturers in Europe operating 22 sites in eight European countries, Asia and USA. Supports BHP's Pain Management portfolio.

barretthodgson.com
Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Listed Pakistani pharma company partnering with global MNCs (e.g., Gilead for hepatitis C); comparable MNC in-licensing model and branded generics portfolio.

TypeDirect peer
Description

Pakistani pharma manufacturer with strong primary care and chronic disease franchises; comparable mid-to-large field force and therapeutic breadth.

TypeDirect peer
Description

Pakistani pharma company with similar therapeutic breadth (cardio, diabetes, CNS) and large field force; competes head-to-head with BHP in chronic disease categories.

TypeDirect peer
Description

Pakistan-based branded pharmaceutical manufacturer with a broad multi-therapeutic portfolio and large field force; one of the most direct top-15 competitors to BHP in cardiology, anti-infectives and gastroenterology.

TypeDirect peer
Description

Pakistani pharma manufacturer focused on branded generics across cardiovascular, anti-infective and CNS; similar scale and distribution-driven GTM model to BHP.

TypeDirect peer
Description

Top-tier Pakistani pharma manufacturer with strong cardiovascular, gastroenterology and anti-infective franchises; comparable therapeutic mix and hospital-channel focus.

TypeBroad incumbent
Description

Global emerging-markets pharma major with a strong presence in respiratory, anti-infective and cardiovascular; serves as a broader incumbent benchmark for therapeutic mix, regulatory standards and pricing dynamics relevant to BHP.

TypeDirect peer
Description

Pakistani pharma manufacturer competing in similar antibiotic, cardiac and respiratory categories; comparable scale and distribution-driven model.

9The Searle Company
TypeDirect peer
Description

Listed Pakistani pharma company with a comparable multi-therapeutic branded portfolio, in-licensed MNC brands and similar distribution model; directly competes with BHP across multiple therapy areas.

TypeDirect peer
Description

Pakistan-based contract and branded pharmaceutical manufacturer with multi-therapeutic portfolio and strong export orientation; overlaps with BHP in manufacturing and product mix.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Barrett Hodgson

Pharmaceuticalsbarretthodgson.com

Barrett Hodgson Pakistan is a Karachi-based pharmaceutical company ranking among Pakistan's top 15, manufacturing and distributing over 100 brands and 240 formulations across cardiovascular, respiratory, ophthalmology, and pain management through a 1,100+ member field force.

What Barrett Hodgson does

Barrett Hodgson Pakistan (Pvt.) Ltd. is a Karachi-headquartered, private pharmaceutical company founded in 1992 and formally inaugurated in 1996. It operates as part of the Habib family enterprise and is owned by The Salim Habib Education Foundation (TSHEF), a non-profit established in 2007 that channels profits into educational initiatives including Barrett Hodgson University in Karachi and Barrett Hodgson College in Toba Tek Singh. The company ranks among the top 15 of approximately 700 pharmaceutical companies in Pakistan by turnover, with disclosed revenue of Rs. 11.28 Billion and a stated target of Rs. 20 Billion.

The company manufactures and distributes a portfolio of more than 100 brands and 240 formulations across cardiovascular, respiratory, anti-infective, ophthalmology, pain management, gastroenterology, diabetes, neurology, and other therapeutic areas; 24 brands lead their respective molecules. Approximately 5 of every 6 product representations originate from co-development partnerships with global MNCs, namely AstraZeneca (Losec, Plendil, Betaloc-ZOK), Astellas (Cefspan, Cefizox), Allergan (Lumigan, Alphagan, Combigan, Botox), LTL Pharma (cephalosporin range), and The Aenova Group (pain management). Manufacturing is cGMP-compliant with a Quality Management System based on ICH, WHO, and PIC/s guidelines; SAP S/4 HANA ERP was deployed in 2018 as the first such implementation in a Pakistani pharma company, and a new sterile area was approved by DRAP in 2020.

The business model is a prescription-driven pharma distribution business monetized through one-time product sales across Pakistan via a 1,100+ strong field force and 72 distributors reaching approximately 2,600 towns, 31,000 pharmacies, and 310+ hospital and institutional customers. Commercial operations are organized into therapeutic divisions led by Deputy Commercial Directors under a layered Area Manager / Regional Head structure, with supporting medical detailing, CME programs, patient awareness camps, and social media marketing. The company is currently expanding manufacturing capacity (sterile, tablet, liquid), constructing a Lahore warehouse, and acquiring a 2-acre plot in Karachi for portfolio diversification beyond pharmaceuticals, consistent with its growth trajectory and CSR commitments under TSHEF.

Barrett Hodgson firmographics

Firmographics
Name
Barrett Hodgson
Legal name
Barrett Hodgson Pakistan (Pvt.) Ltd.
Website
https://barretthodgson.com
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Barrett Hodgson Pakistan is a Karachi-based pharmaceutical company ranking among Pakistan's top 15, manufacturing and distributing over 100 brands and 240 formulations across cardiovascular, respiratory, ophthalmology, and pain management through a 1,100+ member field force.
Ownership category
akta.pro rank

Barrett Hodgson industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Pharmaceutical manufacturing
  • Generic medicines
  • Therapeutic formulations
  • Cardiovascular drugs
  • Cephalosporin antibiotics

Where Barrett Hodgson is headquartered

Location

Headquarters

HQ city
Karachi
HQ country
Pakistan
HQ region
Asia

Offices4 records

Markets served

Barrett Hodgson business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Revenue generated from sale of pharmaceutical products across multiple therapeutic categories through direct sales force and distribution network covering 72 distributors, 2,600 towns, 31,000 pharmacies, and 310+ hospital/institution customers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Barrett Hodgson product offering

Product offering

Core offering

Barrett Hodgson Pakistan manufactures and distributes a portfolio of over 100 pharmaceutical brands and 240 formulations across cardiovascular, respiratory, anti-infective, ophthalmology, pain management, gastroenterology, diabetes, and neurology therapeutic areas. The company also represents products from five global partners including AstraZeneca, Astellas, Allergan, LTL Pharma, and Aenova Group across Pakistan through a 72-distributor network covering 2,600 towns, 31,000 pharmacies, and 310+ hospital/institutional customers.

Product overview

Barrett Hodgson Pakistan (BHP) is a pharmaceutical company ranking among the top 15 in Pakistan with over 100 brands and 240 formulations. The portfolio includes products from five international business partners: AstraZeneca (cardiovascular/respiratory: Losec, Plendil, Betaloc-ZOK), Astellas (cephalosporin antibiotics: Cefspan, Cefizox), Allergan (ophthalmology: Lumigan, Alphagan, Combigan; and therapeutics/cosmetics: Botox), LTL Pharma (cephalosporin range), and The Aenova Group (pain management). Core products span therapeutic areas including cardiovascular, respiratory, anti-infective, ophthalmology, pain management, gastroenterology, diabetes, and neurology. 24 brands are market leaders. The company also operates through The Salim Habib Education Foundation (TSHEF) for CSR and education initiatives, and is diversifying into non-pharmaceutical businesses.

Differentiator

Problem solved

Functional benefit

Products and services

  • Acicon
  • AciReg Esomeprazole 20mg, 40mg Capsule and 40mg IV Infusion for proton pump inhibition; sold through Pakistan pharmacy and hospital distribution.
  • Aerokast Montelukast sodium 4mg Sachet, 4mg and 5mg Chewable Tabs, 10mg Tabs for respiratory conditions; sold through Pakistan pharmacy and hospital distribution.
  • Alphagan Ophthalmic Solution Brimonidine tartrate 0.2% ophthalmic solution for glaucoma; marketed in Pakistan in partnership with Allergan.
  • Botox Botulinum Toxin Type A for therapeutic and cosmetic applications, distributed in Pakistan in partnership with Allergan.
  • Febrol Paracetamol-based analgesic in Tablet, Suspension and DS Suspension forms for pain and fever management; distributed across Pakistan pharmacies.
  • Inocef Ceftriaxone 250mg and 500mg IM Injection and 250mg, 500mg, 1000mg and 2000mg IV Injection for anti-infective therapy; supplied to Pakistani hospitals and pharmacies.
  • Nebicare Nebivolol 2.5mg, 5mg and 10mg Tablet for cardiovascular conditions; launched in 2017 and sold through Pakistani pharmacy and hospital distribution.
  • AV-Sartan Amlodipine+Valsartan combination tablet in 5mg+80mg, 5mg+160mg and 10mg+160mg strengths for hypertension; launched in 2017.
  • Gutset Itopride Hydrochloride 50mg Tablet for gastrointestinal disorders; launched in 2017.
  • Lumigan Ophthalmic Solution Bimatoprost 0.03% ophthalmic solution for glaucoma; marketed in Pakistan in partnership with Allergan.
  • Combigan Ophthalmic Solution Brimonidine tartrate/Timolol maleate 0.2%/0.5% ophthalmic solution for glaucoma; marketed in Pakistan in partnership with Allergan.
  • Cefspan Cefixime 100mg/5ml Suspension, 200mg/5ml DS Suspension and 400mg Capsule for anti-infective therapy; marketed in Pakistan in partnership with Astellas.
  • Cefizox IV-IM Injection Ceftizoxime sodium 250mg, 500mg and 1000mg IV/IM Injection for anti-infective therapy; marketed in Pakistan in partnership with Astellas.
  • Mobikare Diclofenac Sodium in Capsule, Injection, Plus Tablet, and Gel formulations for pain management; supported by Aenova Group partnership.
  • Diabold Glimepiride 1, 2, 3 and 4mg Tablet for diabetes management; distributed through Pakistan pharmacy and hospital network.
  • Baristat Febuxostat 40mg and 80mg Tablet for gout management; distributed through Pakistan pharmacy network.
  • Rivaclot Rivaroxaban 2.5mg, 10mg, 15mg and 20mg Tablet for anticoagulation therapy; distributed through Pakistan pharmacy network.
  • RosuBar Rosuvastatin 5mg, 10mg and 20mg Tablet for lipid management; distributed through Pakistan pharmacy network.
  • Neugalin Pregabalin 25mg, 50mg, 75mg, 100mg and 150mg Capsule for neurological conditions including neuropathic pain.
  • S-gliptin Sitagliptin and Sitagliptin+Metformin HCI combination tablet for diabetes management.
  • Vilcret Plus Vildagliptin+Metformin HCI tablet in 50mg+500mg, 50mg+850mg and 50mg+1000mg strengths for diabetes management.
  • AstraZeneca Brand Portfolio (Losec, Plendil, Betaloc-ZOK) Cardiovascular and respiratory products from partner AstraZeneca represented in Pakistan including Losec (Omeprazole), Plendil (Felodipine), and Betaloc-ZOK (Metoprolol succinate).
  • Astellas Cephalosporin Range (Cefspan, Cefizox) Cephalosporin antibiotic products from partner Astellas including Cefspan (Cefixime) and Cefizox (Ceftizoxime sodium) in various injectable and oral formulations.
  • Allergan Ophthalmology Brand Portfolio (Lumigan, Alphagan, Combigan, Botox) Ophthalmology and therapeutics products from partner Allergan including Lumigan (Bimatoprost), Alphagan (Brimonidine), Combigan (Brimonidine/Timolol), and Botox for therapeutic and cosmetic applications.
  • LTL Pharma Cephalosporin Range Cephalosporin antibiotic range acquired from partner LTL Pharma Co., Ltd. (Japan) ensuring stable supply of original-quality products.
  • Aenova Pain Management Portfolio Pain management products supported by partner The Aenova Group (Germany), a global contract manufacturer with 22 sites across Europe, Asia and USA.

Quantifiable outcome

  • Ranked among top 15 pharmaceutical companies in Pakistan out of 700 companies
  • +2 more outcomes

Companies that use Barrett Hodgson

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Barrett Hodgson technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Barrett Hodgson partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • AstraZenecacoreStrategic or Co-development PartnerBritish-Swedish multinational pharmaceutical company with operations in more than 100 countries. BHP represents AstraZeneca in Pakistan through different therapeutic segments including Cardiovascular and Respiratory. Key brands marketed include Losec, Plendil, and Betaloc-ZOK.
  • AstellascoreStrategic or Co-development PartnerJapanese pharmaceutical company formed in 2005 with merger of Yamanouchi and Fujisawa. BHP represents Astellas in Pakistan through Cephalosporin Antibiotics segment. Markets different formulations of Cefspan and Cefizox.
  • AllergancoreStrategic or Co-development PartnerUS-based global multi-specialty ophthalmic healthcare company established in 1948. BHP markets Allergan's ophthalmology brands including Lumigan, Alphagan, Combigan, and Botox for therapeutics and cosmetics.
  • LTL Pharma Co. Ltd.coreStrategic or Co-development PartnerJapanese subsidiary of Japan Established Medicine Corporation. Ensures stable supply of products maintaining original product reliability, quality, efficacy and safety. BHP acquires Cephalosporin range from LTL Pharma.
  • The Aenova GroupcoreStrategic or Co-development PartnerGlobal leader in pharmaceutical and healthcare industries with emphasis on innovative technologies and high quality standards. One of the leading contract manufacturers in Europe operating 22 sites in eight European countries, Asia and USA. Supports BHP's Pain Management portfolio.

Scale indicators6 records

Recent moves12 records

Expansion highlights6 records

Barrett Hodgson competitors and assessment

Company assessment

Direct peers

  • Ferozsons Laboratories: Listed Pakistani pharma company partnering with global MNCs (e.g., Gilead for hepatitis C); comparable MNC in-licensing model and branded generics portfolio.
  • Highnoon Laboratories: Pakistani pharma manufacturer with strong primary care and chronic disease franchises; comparable mid-to-large field force and therapeutic breadth.
  • PharmEvo: Pakistani pharma company with similar therapeutic breadth (cardio, diabetes, CNS) and large field force; competes head-to-head with BHP in chronic disease categories.
  • Getz Pharma: Pakistan-based branded pharmaceutical manufacturer with a broad multi-therapeutic portfolio and large field force; one of the most direct top-15 competitors to BHP in cardiology, anti-infectives and gastroenterology.
  • Hilton Pharma: Pakistani pharma manufacturer focused on branded generics across cardiovascular, anti-infective and CNS; similar scale and distribution-driven GTM model to BHP.
  • AGP Limited: Top-tier Pakistani pharma manufacturer with strong cardiovascular, gastroenterology and anti-infective franchises; comparable therapeutic mix and hospital-channel focus.
  • Bosch Pharmaceuticals: Pakistani pharma manufacturer competing in similar antibiotic, cardiac and respiratory categories; comparable scale and distribution-driven model.
  • The Searle Company: Listed Pakistani pharma company with a comparable multi-therapeutic branded portfolio, in-licensed MNC brands and similar distribution model; directly competes with BHP across multiple therapy areas.
  • Macter Pharma: Pakistan-based contract and branded pharmaceutical manufacturer with multi-therapeutic portfolio and strong export orientation; overlaps with BHP in manufacturing and product mix.

Broad incumbents

  • Cipla: Global emerging-markets pharma major with a strong presence in respiratory, anti-infective and cardiovascular; serves as a broader incumbent benchmark for therapeutic mix, regulatory standards and pricing dynamics relevant to BHP.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Barrett Hodgson social profiles

Digital presence

Barrett Hodgson financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Barrett Hodgson leadership team

Management profile

Number of profiles

Profiles6 records

Barrett Hodgson funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Barrett Hodgson M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Barrett Hodgson

What does Barrett Hodgson do?

Barrett Hodgson Pakistan manufactures and distributes a portfolio of over 100 pharmaceutical brands and 240 formulations across cardiovascular, respiratory, anti-infective, ophthalmology, pain management, gastroenterology, diabetes, and neurology therapeutic areas. The company also represents products from five global partners including AstraZeneca, Astellas, Allergan, LTL Pharma, and Aenova Group across Pakistan through a 72-distributor network covering 2,600 towns, 31,000 pharmacies, and 310+ hospital/institutional customers.

Is Barrett Hodgson a public or private company?

Barrett Hodgson is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Barrett Hodgson founded?

Barrett Hodgson was founded in 1996. It employs 501 to 1,000 people.

Where is Barrett Hodgson based?

Barrett Hodgson is headquartered in Karachi, Pakistan, in the Asia region.

How does Barrett Hodgson make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Barrett Hodgson's main competitors?

Direct peers on record are Ferozsons Laboratories, Highnoon Laboratories, PharmEvo, Getz Pharma, Hilton Pharma, AGP Limited, Bosch Pharmaceuticals, The Searle Company and Macter Pharma. Cipla is listed as a broad incumbent.

Does Barrett Hodgson have an API?

No public API is recorded for Barrett Hodgson.

What industry is Barrett Hodgson in?

Barrett Hodgson's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales